The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2016: 33 negotiations are currently underway with 8 files (including 2 biosimilars) added since the last update of May 31, 2016: Abilify (aripiprazole): used for the treatment of schizophrenia and related ...
In February 2015, PDCI Market Access (PDCI) released a report entitled pCPA Negotiation Guidelines. That report, which was a collaboration between the pan-Canadian Pharmaceutical Alliance (pCPA) and PDCI, was meant to provide guidance to manufacturers on pCPA’s expectations surrounding negotiations. Although the pCPA Negotiation Guidelines report outlined how manufacturers should ...
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2016: 23 negotiations are currently underway with 5 files added since the last update on March 31, 2016: Arnuity Ellipta (fluticasone furoate): used for the treatment of asthma; Breo Ellipta (fluticasone furoate/vilanterol): used for ...
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued the First Principles for Subsequent Entry Biologics (SEBs) to guide negotiations and inform expectations. These principles are now available on the pCPA website, found here. The pCPA has also updated the status of negotiations on brand name drugs, included in ...
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued manufacturers a notification of first principles for subsequent entry biologics (SEBs) to guide negotiations and inform expectations. This information has not yet been posted on the pCPA website but is being shared with their permission. Please see below for a copy ...
pCPA February Update – Federal Drug Plans officially join the pCPA and the full Office team is now in place
In a recent update released to their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced 2 significant developments: The Federal Drug Plans are now participating in the pCPA; and The Office of the pCPA (the Office) is now fully staffed. On January 19, 2016 the Government of Canada issued a News Release ...
Suzanne McGurn, the Executive Officer of the Ontario Public Drug Programs, issued a statement on behalf of the Pan Canadian Pharmaceutical Alliance (pCPA), on February 16, 2016 detailing the end of negotiations with manufacturer Alexion for the listing of Soliris. Please see the following article for more information.
As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014. Through this newly named report series, the PMPRB monitors and reports on: the latest developments in generic drug pricing and markets ...
Modifications to the Procedure for Filing a Drug Submission Application for Generic Drugs with INESSS
Since Québec is now participating in the pan-Canadian Pharmaceutical Alliance (pCPA), INESSS recently communicated that information sharing has now become necessary to ensure greater efficiency when conducting drug reviews. As of February 15, 2016, a supplementary document, supporting authorization of information sharing with pCPA, must accompany any drug submission application pertaining ...
PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers. With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing ...